How to Get Dayvigo (Lemborexant) in Texas

What Is Dayvigo and Why Does Access Matter in Texas?

Lemborexant is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for treating insomnia in adults with difficulty falling asleep, staying asleep, or both. Unlike older sedative-hypnotics such as zolpidem, DORAs work by blocking wake-promoting orexin neuropeptides rather than broadly suppressing CNS activity [1]. Texas has roughly 30 million residents, and an estimated 35% of U.S. adults report sleeping fewer than seven hours per night according to CDC surveillance data. That creates substantial demand for targeted insomnia pharmacotherapy across the state.

The FDA-approved prescribing information lists two dose strengths: 5 mg (recommended starting dose) and 10 mg. Clinicians titrate based on response and tolerability, with 10 mg reserved for patients who do not respond adequately to 5 mg. Because lemborexant is a Schedule IV controlled substance under the DEA, Texas prescribers must comply with both federal and state controlled-substance regulations when issuing a prescription.

Who Can Prescribe Dayvigo in Texas?

Any Texas-licensed prescriber with Schedule IV authority can write a Dayvigo prescription. That includes physicians (MD and DO), nurse practitioners holding full prescriptive authority under the Texas Board of Nursing, and physician assistants operating under a physician delegation agreement that covers Schedule IV drugs. Texas is not a full-practice-authority state for NPs. NPs must maintain a collaborative agreement with a physician to prescribe controlled substances, though a 2023 legislative update simplified some supervision documentation requirements.

A sleep medicine specialist is not required. Primary care physicians prescribe the majority of insomnia medications in the U.S. The American Academy of Family Physicians recommends cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy appropriate when CBT-I alone is insufficient or unavailable. Your prescriber should document a clinical sleep history and rule out secondary causes such as obstructive sleep apnea, restless legs syndrome, or medication-induced insomnia before starting Dayvigo.

Telehealth Prescribing Rules for Dayvigo in Texas

Texas permits telehealth prescribing of Schedule IV controlled substances. Under Texas Occupations Code Chapter 111, a prescriber-patient relationship can be established via synchronous audio-video visit if the prescriber uses a platform that meets HIPAA requirements and maintains appropriate documentation. A DEA-registered prescriber located in Texas, or one holding a Texas-specific DEA registration, may prescribe Dayvigo via telehealth to a Texas patient.

The Ryan Haight Act at the federal level generally requires an in-person evaluation before prescribing controlled substances online. However, DEA telemedicine exemptions expanded during the public health emergency have been extended through DEA rulemaking. As of early 2026, DEA's proposed telemedicine rules allow an initial 30-day Schedule III through V prescription via telehealth, with a follow-up requirement for continued prescribing [2]. Patients should verify that their telehealth provider's prescribing workflow complies with the most current DEA policy.

Several national telehealth platforms serve Texas patients seeking insomnia treatment. HealthRX connects patients with licensed clinicians who can evaluate insomnia symptoms, order any necessary labs, and prescribe Dayvigo when clinically appropriate. The entire process, from intake to prescription, typically takes one to three business days.

What Labs or Evaluations Are Needed Before Starting Dayvigo?

No specific laboratory tests are required before prescribing lemborexant. The drug is metabolized primarily by CYP3A4, so a prescriber will review your medication list for CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and inducers (e.g., rifampin, carbamazepine). Moderate CYP3A4 inhibitors require a dose reduction to 5 mg; strong CYP3A4 inhibitors contraindicate use entirely [1].

A clinical evaluation should include screening for narcolepsy and cataplexy, since blocking orexin receptors could theoretically worsen cataplexy symptoms. The prescriber may use validated tools like the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI) to document baseline severity. A polysomnography or home sleep test is not routinely needed for primary insomnia but may be ordered if sleep apnea is suspected. The Endocrine Society and other specialty bodies recommend checking thyroid function if clinical signs suggest thyroid-related sleep disruption, though this is not specific to lemborexant prescribing.

Liver function should be considered in patients with hepatic impairment. The FDA label recommends a maximum dose of 5 mg in patients with moderate hepatic impairment (Child-Pugh B) and does not recommend use in severe hepatic impairment (Child-Pugh C) [1].

The SUNRISE Clinical Trial Evidence

The SUNRISE-1 trial (N=1,006) was a phase 3, randomized, double-blind, placebo- and active-comparator study that evaluated lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg in adults aged 55 and older with insomnia disorder. At the primary endpoint of one month, lemborexant 10 mg reduced latency to persistent sleep (LPS) by 10.5 minutes more than placebo (P<0.001). Both lemborexant doses significantly improved wake after sleep onset (WASO) compared to placebo and compared to zolpidem ER at month one [3].

A secondary finding from SUNRISE-1 that clinicians should note: zolpidem ER did not separate from placebo on the WASO endpoint at one month, while both lemborexant doses did. This suggests a potential advantage for DORAs in patients whose primary complaint is middle-of-the-night or early-morning awakening rather than sleep-onset latency alone.

The SUNRISE-2 trial (N=949) evaluated long-term safety and efficacy over 12 months. Lemborexant maintained its efficacy on subjective sleep-onset latency and subjective WASO across the study period, with no evidence of rebound insomnia upon discontinuation at month 12 [4]. Treatment-emergent adverse events were predominantly mild. Somnolence occurred in 10% of patients on lemborexant 10 mg versus 1% on placebo. No next-morning driving impairment signal was detected at the 5 mg dose in the SUNRISE-1 driving substudy.

Dr. Margaret Moline, then head of Eisai's neurology business group, stated during the FDA advisory committee review: "Lemborexant is designed to allow the normal sleep process to occur by reducing the wake drive, rather than inducing sedation through GABAergic pathways."

Insurance Coverage and Prior Authorization in Texas

Commercial insurance plans in Texas generally cover Dayvigo, though most require prior authorization and step therapy. Step therapy typically means the patient must document an inadequate response to, or intolerance of, at least one generic sleep medication (usually zolpidem or eszopiclone) before the plan will approve Dayvigo. Documentation your prescriber should have ready for prior authorization includes:

• A confirmed insomnia disorder diagnosis (ICD-10 G47.00 or G47.01)
• Records of prior formulary medication trials with dates, doses, and reason for discontinuation
• Clinical notes describing symptom severity and functional impairment
• The prescriber's rationale for selecting lemborexant over formulary alternatives

Texas Medicaid does not cover Dayvigo for insomnia. The Texas Medicaid Preferred Drug List restricts orexin receptor antagonist coverage to narrow indications that do not include primary insomnia. Patients on Texas Medicaid may need to explore manufacturer assistance programs.

Eisai's Dayvigo Savings Program can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 to $30 per fill, depending on plan structure. Cash prices for a 30-day supply of Dayvigo range from approximately $380 to $450 at Texas retail pharmacies without insurance, according to GoodRx pricing data from Q1 2026. Discount programs through GoodRx, RxSaver, or similar aggregators can reduce this to $300 to $370 at select pharmacies.

Pharmacy Access and 503A Compounding in Texas

Dayvigo is available at all major chain pharmacies in Texas, including CVS, Walgreens, H-E-B Pharmacy, and Walmart Pharmacy. Because it is a Schedule IV controlled substance, the prescription cannot be called in verbally. It must be transmitted electronically via EPCS (Electronic Prescribing for Controlled Substances) or issued on a written tamper-resistant prescription pad.

Mail-order pharmacy is an option for Texas patients who prefer home delivery. Express Scripts, OptumRx, and CVS Caremark all carry Dayvigo. Most mail-order pharmacies offer 90-day supplies, which can reduce per-unit cost on commercial plans. Delivery timelines range from 7 to 10 business days for initial fills.

Texas licenses 503A compounding pharmacies under the Texas State Board of Pharmacy. These pharmacies can compound lemborexant into alternative dosage forms (such as a liquid suspension for patients with swallowing difficulties) if a prescriber writes a patient-specific prescription. Texas 503A pharmacies cannot ship compounded controlled substances across state lines. The compounded product must be dispensed within Texas, and the pharmacy must maintain a valid Texas controlled-substance registration. Patients considering a compounded formulation should confirm that their specific 503A pharmacy holds the appropriate registrations.

Transferring a Dayvigo Prescription to Texas

If you are relocating to Texas or visiting for an extended period, transferring an existing Dayvigo prescription is possible with some limitations. Under federal law, Schedule III through V prescriptions may be transferred between pharmacies one time only. The receiving Texas pharmacy contacts the originating pharmacy to initiate the transfer. Both pharmacies must document the transfer in their records.

For patients moving permanently, the more practical approach is establishing care with a Texas-licensed prescriber who can write new prescriptions. Bring your previous medical records, including the original prescriber's notes, sleep study results (if applicable), and your current dose and response history. This also ensures continuity of monitoring.

A prescriber in another state cannot prescribe Dayvigo to a patient physically located in Texas unless that prescriber holds a Texas medical license. Texas does not participate in the Interstate Medical Licensure Compact for telemedicine prescribing of controlled substances.

Safety Considerations and Monitoring

The most common adverse effects reported in clinical trials were somnolence (10% at 10 mg), headache (6%), and unusual dreams (3%) [3]. Lemborexant does not produce the same degree of next-morning residual sedation associated with longer-acting benzodiazepine receptor agonists, though patients should still be cautioned about morning drowsiness during the first few days of treatment.

The FDA label includes warnings about complex sleep behaviors (sleepwalking, sleep-driving, engaging in activities while not fully awake), which are rare but documented across all hypnotic classes. Patients should be instructed to take Dayvigo only when they can stay in bed for at least seven hours. The drug should not be combined with alcohol or other CNS depressants.

A Cochrane systematic review on orexin receptor antagonists for insomnia (2023) concluded that DORAs provide modest but statistically significant improvements in subjective and objective sleep measures, with an acceptable short-term safety profile. The review noted insufficient evidence to determine long-term risks beyond 12 months. Follow-up visits every three to six months are a reasonable monitoring interval for patients on ongoing Dayvigo therapy, consistent with AAFP insomnia management recommendations [5].

Lemborexant 5 mg at bedtime is the recommended starting dose for all adult patients, including those aged 65 and older. No dose adjustment is needed based on age alone [1].